CAS: 60732-17-4; 2,5-Dimethoxybenzylbromide

上下游产品

2,5-dimethoxybenzyl alcohol 2,5-dimethoxy toluene N-Bromosuccinimide formaldehyd 1,4-dimethoxy-2-methoxymethyl-benzene 2-(2,5-dimethoxyphenyl)acetonitrile 2,5,2',5'-tetramethoxy-bibenzyl 1-(2,5-dimethoxy-benzyl)-2-[1,3]dioxolan-2-yl-pyridinium; bromide

📜对苯二甲醚置于sodium Tetrahydroborate,氢溴酸,四氯化钛体系中,用 甲醇,二氯甲烷,水 作为反应溶剂,化学反应 7.5H,反应生成 2,5-二甲氧基苄溴
参考文献:一种2,5-二甲氧基苯乙酸的制备方法
标题:一种2,5-二甲氧基苯乙酸的制备方法
摘要:本发明属于药物合成技术领域,尤其涉及一种2,5‑二甲氧基苯乙酸的制备方法,该方法包括以下步骤:A,将1,4‑二甲氧基苯在甲酰化体系下进行反应,得到2,5‑二甲氧基苯甲醛;b,取步骤a得到的2,5‑二甲氧基苯甲醛与还原剂反应,反应体系经过萃取,接着合并有机相,干燥,减压浓缩与蒸馏粗品,得到2,5‑二甲氧基苯甲醇;c,取步骤b得到的2,5‑二甲氧基苯甲醇与溴化试剂反应,得到2‑溴甲基‑1,4‑二甲氧基苯;d,取步骤c得到的2‑溴甲基‑1,4‑二甲氧基苯与镁或丁基锂,二氧化碳置于溶剂中反应得到2,5‑二甲氧基苯乙酸.本发明方法得到的2,5‑二甲氧基苯乙酸的收率以及总收率均高于通过willgerodt‑kindler法合成的2,5‑二甲氧基苯乙酸.

专利信息

专利号:US-7125906-B2
优先权日:2002-04-03
标题 :Indole derivatives having anti-angiogenetic activity
发明人：ARNOULD JEAN-CLAUDE
权利人:ASTRAZENECA AB
摘要:The invention relates to the use of a compound of Formula (I), for the manufacture of a medicament to inhibit and/or reverse and/or alleviate symptoms of angiogenesis and/or any disease state associated with angiogenesis: n nwherein: X, p, q, R 1 , R 2 , R 3 , R 4 , and R 5 are as defined in the description. The invention also related to use of compounds of Formula (I) as medicaments and also to novel compounds of Formula (I). The invention further provides pharmaceutical compositions of compounds of Formula (I) and processes for the synthesis of compounds of Formula (I).

专利号:CN-114787122-A
优先权日:2019-08-13
标题:Novel polycondensation synthesis of 2-methoxymethyl-p-phenylenediamine

专利号:WO-9512588-A1
优先权日:1993-11-05
标 题:Antineoplastic heteronaphthoquinones
发明人：ATTARDO GIORGIO; WANG WUYI; BREINING TIBOR; LI TIECHAO; ST-DENIS YVES; KRAUS JEAN-LOUIS
权利人:IAF BIOCHEM INT; ATTARDO GIORGIO; WANG WUYI; BREINING TIBOR; LI TIECHAO; ST DENIS YVES; KRAUS JEAN LOUIS
摘要:Tricyclic heteronaphthoquinone derivatives, that have antineoplastic activity, are disclosed, together with processes for their synthesis. Some of these antineoplastic compounds have a saccharide moiety. Some members of this structurally distinct group exhibit activity against multiple drug resistant cancer cells.